600511.SHG China National Medicines Corp Ltd
- Market cap
- CNY 21.9B
- P/E
- 11.1x
- P/B
- 1.13x
- ROE
- 10.1%
- Dividend yield
- 2.86%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600511.SHG undervalued?
Graham number600511.SHG trades 25.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China National Medicines Corp Ltd fundamental analysis
No fundamental analysis for China National Medicines Corp Ltd yet.
China National Medicines Corp Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China National Medicines Corp Ltd
China National Medicines Corporation Ltd., together with its subsidiaries, engages in pharmaceutical equipment circulation in China. The company also manufactures and sells new drugs; sells Chinese patent medicines drug sales and western medicines, and medical equipment; and offers dental drug and equipment, warehousing, logistics and import and export agency services. It also serves hospitals, retail pharmacies, and medical institutions. The company was founded in 1999 and …
Full company profileChina National Medicines Corp Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
China National Medicines Corp Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 34.6B | 36.3B | 38.7B | 44.6B | 40.4B | 46.5B | 45.5B | 49.7B | 50.6B | 52.5B | 54.1B |
| Gross Profit | 2.45B | 2.83B | 3.42B | 3.91B | 3.14B | 3.62B | 3.82B | 3.99B | 3.59B | 3.46B | 3.42B |
| Operating Income | 1.54B | 1.77B | 2.04B | 2.44B | 1.91B | 2.45B | 2.69B | 2.94B | 2.68B | 2.62B | 2.17B |
| EBITDA | 1.60B | 1.80B | 1.93B | 2.37B | 1.67B | 2.15B | 2.42B | 2.49B | 2.21B | 2.87B | 2.56B |
| Net Income | 990M | 1.14B | 1.40B | 1.60B | 1.38B | 1.75B | 1.96B | 2.15B | 2.00B | 2.00B | 1.97B |
| EPS | 1.43 | 1.55 | 1.83 | 2.11 | 1.83 | 2.32 | 2.60 | 2.84 | 2.65 | 2.65 | 2.61 |
| Balance Sheet | |||||||||||
| Total Assets | 7.40B | 20.2B | 21.5B | 24.2B | 24.9B | 27.5B | 29.6B | 32.5B | 34.9B | 36.7B | 36.8B |
| Total Liabilities | 3.38B | 10.7B | 10.9B | 12.0B | 11.8B | 13.1B | 13.7B | 14.9B | 16.0B | 16.4B | 15.7B |
| Shareholders' Equity | 3.52B | 8.18B | 9.23B | 10.5B | 11.4B | 12.8B | 14.2B | 15.8B | 17.1B | 18.5B | 19.4B |
| Cash & Short-term Investments | 1.68B | 5.46B | 5.10B | 5.70B | 6.22B | 7.32B | 8.90B | 10.9B | 10.9B | 11.5B | 8.16B |
| Total Debt | 2.36B | 1.24B | 1.03B | 558M | 802M | 713M | 515M | 473M | 746M | 4.58B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 591M | 1.07B | 982M | 1.78B | 1.30B | 1.96B | 2.40B | 2.73B | 1.66B | 2.01B | - |
| Capital Expenditure | 39.9M | 73.2M | 132M | 85.7M | 69.1M | 95.1M | 130M | 145M | 131M | 68.2M | 55.3M |
| Free Cash Flow | 551M | 1.00B | 849M | 1.69B | 1.23B | 1.86B | 2.27B | 2.58B | 1.53B | 1.94B | -3.26B |
| Ratios | |||||||||||
| ROE | 28.1% | 14.0% | 15.2% | 15.2% | 12.1% | 13.7% | 13.8% | 13.6% | 11.7% | 10.8% | 10.1% |
| ROA | 13.4% | 5.7% | 6.5% | 6.6% | 5.6% | 6.4% | 6.6% | 6.6% | 5.7% | 5.4% | 5.3% |
| Net Profit Margin | 2.9% | 3.1% | 3.6% | 3.6% | 3.4% | 3.8% | 4.3% | 4.3% | 4.0% | 3.8% | 3.6% |
| Debt to Equity | 0.67x | 0.15x | 0.11x | 0.05x | 0.07x | 0.06x | 0.04x | 0.03x | 0.04x | 0.25x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
China National Medicines Corp Ltd dividends
- Dividend yield
- 2.86%
- Forward dividend
- 0.80 CNY
- Payout ratio
- 31.3%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 626M | 0.83 | 31.3% |
| 2024 | CNY 682M | 0.90 | 34.1% |
| 2023 | CNY 590M | 0.78 | 27.5% |
| 2022 | CNY 528M | 0.70 | 26.9% |
| 2021 | CNY 415M | 0.55 | 23.7% |
| 2020 | CNY 481M | 0.64 | 34.8% |
| 2019 | CNY 306M | 0.40 | 19.1% |
| 2018 | CNY 516M | 0.67 | 36.8% |
| 2017 | CNY 259M | 0.35 | 22.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jun 3, 2009.
Who owns China National Medicines Corp Ltd
- Insiders 59.60%
- Institutions 13.10%
- Public & others 27.30%
- Shares outstanding 755M
- Free float 281M
China National Medicines Corp Ltd company profile
- Company name
- China National Medicines Corp Ltd
- Ticker
- 600511.SHG
- ISIN
- CNE000001D56
- Exchange
- Shanghai Stock Exchange
- Listed since
- Nov 12, 2002
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 3,024
- Fiscal year end
- December
- Address
- Floor 6-9, West Tower, Beijing, China, 100077
- Phone
- 86 10 6727 1828
- Website
- cncm.com.cn
About China National Medicines Corp Ltd
China National Medicines Corporation Ltd., together with its subsidiaries, engages in pharmaceutical equipment circulation in China. The company also manufactures and sells new drugs; sells Chinese patent medicines drug sales and western medicines, and medical equipment; and offers dental drug and equipment, warehousing, logistics and import and export agency services. It also serves hospitals, retail pharmacies, and medical institutions. The company was founded in 1999 and is based in Beijing, China. China National Medicines Corporation Ltd. operates as a subsidiary of Sinopharm Group Co. Ltd.
China National Medicines Corp Ltd management
7- Mr. Yuetao LiuChairman & Acting GM · born 1972
- Mr. Chen FeiChief Financial Officer · born 1976
- Ms. Lichun LuoGeneral Counsel, Secretary of the Board & Chief Compliance Officer · born 1982
- Ms. Ting ZhangEmployee Director · born 1980
- Ms. Zhuo Yuan XiaoDeputy General Manager · born 1978
- Mr. Lei TangDeputy General Manager · born 1972
- Xinlei LiAccounting Supervisor